Kidney cancer treatment depends heavily on the size of the tumor and whether it has spread. For tumors caught early and confined to the kidney, surgery to remove part or all of the kidney is the primary treatment, and the five-year survival rate at this stage is about 94%. When the cancer has spread to distant sites, combination drug therapies using immunotherapy and targeted medicines have become the standard approach, though survival rates drop significantly. Here’s what each treatment looks like and when it’s used.
Active Surveillance for Small Tumors
Not every kidney tumor needs immediate treatment. For solid tumors smaller than 2 centimeters, or tumors that are predominantly cystic, monitoring with regular imaging is a reasonable first step. This approach, called active surveillance, involves periodic scans to track whether the tumor is growing and how fast.
The American Urological Association identifies specific triggers that shift the recommendation from watching to treating: a tumor larger than 3 centimeters, growth faster than 5 millimeters per year, an infiltrative appearance on imaging, or aggressive cell type on biopsy. Many small kidney tumors grow slowly or not at all, so surveillance spares some people from surgery they may never need. If the tumor does start showing worrisome changes, treatment can begin at that point without compromising outcomes.
Surgery: Partial vs. Full Kidney Removal
Surgery remains the most effective treatment for kidney cancer that hasn’t spread. The two main options are removing just the tumor along with a margin of healthy tissue (partial nephrectomy) or removing the entire kidney (radical nephrectomy).
For tumors classified as T1, roughly 7 centimeters or smaller, guidelines recommend considering a partial nephrectomy whenever technically feasible. The reason is straightforward: removing an entire kidney significantly raises the long-term risk of chronic kidney disease, which in turn increases the chance of cardiovascular problems down the road. Preserving as much healthy kidney tissue as possible protects long-term heart and kidney health.
Radical nephrectomy is still used for larger tumors, tumors in difficult locations, or cases where the cancer has grown into surrounding structures. Most people function well with one kidney afterward, but the risk of developing kidney disease later in life is real and worth discussing with your care team. Both procedures can be done through open surgery or minimally invasive techniques, including robotic-assisted approaches that typically mean shorter hospital stays and faster recovery.
Ablation for Nonsurgical Candidates
For people who can’t undergo surgery due to other health conditions or who have tumors in a remaining solitary kidney, ablation offers an alternative. This technique destroys tumor cells using extreme cold (cryoablation) or heat (radiofrequency ablation), delivered through a needle guided by imaging.
Ablation works best for tumors smaller than 3 centimeters. According to Cleveland Clinic, five-year outcomes for ablation in appropriately selected patients are similar to surgery. The procedure is less invasive, typically done as an outpatient or with a short hospital stay, and preserves more kidney tissue than even a partial nephrectomy.
Stereotactic Radiation for Inoperable Tumors
Kidney cancer was long considered resistant to radiation, but highly focused radiation delivered in just one to five sessions has changed that picture. This approach, called stereotactic body radiation therapy (SBRT), delivers a concentrated dose precisely to the tumor while largely sparing surrounding tissue.
A large international analysis found a median local control rate of 94% with SBRT, and five-year overall survival of about 77%. The five-year local failure rate was just 5.5%. SBRT is primarily used for patients who are medically unable to have surgery, are at high surgical risk, or decline an operation. It’s also a useful option for patients with a solitary kidney, since it preserves kidney function well in most cases, though patients with advanced kidney disease beforehand may not be good candidates.
Immunotherapy and Targeted Drug Combinations
When kidney cancer has spread beyond the kidney, systemic drug therapy becomes the backbone of treatment. Over the past several years, combinations of immunotherapy drugs and targeted therapies have dramatically improved outcomes for advanced kidney cancer.
The targeted drugs work by cutting off the blood supply tumors need to grow. Kidney cancers are especially dependent on forming new blood vessels, which makes them vulnerable to drugs that block a growth signal called VEGF. These medications slow tumor growth by starving it of nutrients and oxygen.
Immunotherapy drugs, specifically checkpoint inhibitors, work differently. They remove the brakes that cancer cells put on the immune system, allowing the body’s own defenses to recognize and attack the tumor.
Current first-line treatment pairs an immunotherapy drug with a targeted therapy drug. Real-world data comparing the major combinations shows that these pairings produce disease control in 78% to 86% of patients, with complete disappearance of detectable cancer in roughly 2% to 7%. For patients with intermediate or poor prognosis, the immunotherapy-plus-targeted-drug combinations kept cancer from progressing for a median of 16 to 25 months, a significant improvement over older treatments. No single combination has proven clearly superior to the others, so the choice often depends on a patient’s overall health and tolerance for side effects.
A second strategy pairs two different immunotherapy drugs together. This dual-immunotherapy approach produces complete responses in about 10% of patients, higher than the targeted combinations, but disease control rates are somewhat lower overall at around 64%, and progression-free survival is shorter, particularly for patients with intermediate or poor risk profiles.
Side Effects of Systemic Treatments
The targeted drugs that block blood vessel growth share a common set of side effects. The most frequent are skin reactions (rashes, hand-foot syndrome), digestive problems (diarrhea, nausea), fatigue, and high blood pressure. Blood pressure elevation occurs with all drugs in this class and needs regular monitoring because uncontrolled hypertension can lead to serious cardiac events. Liver toxicity is another concern, particularly with certain agents that carry specific warnings about liver damage. Serious bleeding, though uncommon, is a recognized risk.
Immunotherapy side effects stem from the immune system becoming overactive. Rather than targeting a specific organ, immune-related reactions can show up almost anywhere: the skin, gut, lungs, liver, thyroid, or other endocrine glands. Most are mild to moderate, but severe immune reactions require prompt treatment, typically with medications that calm the immune response. In the real-world data on combination regimens, serious side effects (grade 3 or higher) occurred in 40% to 61% of patients depending on the specific combination. Regimens with higher disease control rates tended to also have higher rates of side effects, a tradeoff worth understanding when choosing a treatment plan.
Surgery for Metastatic Disease
When kidney cancer has already spread at the time of diagnosis, the role of surgery changes. Removing the primary kidney tumor in this setting is called cytoreductive nephrectomy, and it’s no longer routinely recommended for everyone. A landmark trial (CARMENA) showed that for many patients, starting drug therapy immediately was just as effective as removing the kidney first and then starting drugs.
Immediate surgery still makes sense in select situations: patients in overall good health who don’t yet need systemic therapy, or those with only a few small metastases that can all be completely removed. For patients with poor overall health, large metastatic burden, or aggressive tumor features, surgery is not recommended and drug treatment should begin right away.
One evolving approach is to start drug therapy first and consider removing the kidney later if the patient responds well. This “delayed” surgery lets doctors identify which patients are truly benefiting from treatment before adding the risks of an operation. For patients with just a few metastases, surgical removal of those spots (metastasectomy) can also be considered when complete removal is achievable and imaging confirms the disease isn’t progressing rapidly.
Survival Rates by Stage
How well kidney cancer responds to treatment depends largely on how far it has progressed at diagnosis. Based on data from the National Cancer Institute’s SEER program covering 2016 to 2022, the five-year relative survival rates are:
- Localized (confined to the kidney): 93.6%
- Regional (spread to nearby lymph nodes or tissues): 77.6%
- Distant (spread to remote organs): 20.3%
These are population-level averages, meaning individual outcomes vary based on tumor biology, overall health, and how the cancer responds to treatment. The distant-stage number, while sobering, has been improving steadily as immunotherapy and targeted drug combinations have matured. Patients diagnosed today with metastatic disease have meaningfully better options than those diagnosed even five years ago.